Physician
Philadelphia Retina Associates PC
Philadelphia Retina Associates PC was paid $1.03M by Medicaid between Jan 2018 and Jan 2024, across 11 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 54% of everything it billed.
33Billing provider infoPHILADELPHIA RETINA ASSOCIATES PC
PHILADELPHIA, PA 19152
PHILADELPHIA, PA 19152
33aNPI1104873223assigned 05/27/2006
33bProvider typeRetina Specialist (Ophthalmology) Physician
28Total paid$1.03M
24GClaims22,009
24DCodes billed11
24AFirst – last monthJan 2018 – Jan 2024
Compared with peers
Next to other Retina Specialist (Ophthalmology) Physician providers in Pennsylvania
Rank by total paid#3 of 19
Median peer was paid$14K
This provider vs. median73×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 698 | $13K | |
| 2020 | 1,015 | $84K | |
| 2021 | 6,392 | $419K | |
| 2022 | 7,124 | $263K | |
| 2023 | 6,518 | $240K | |
| 2024incomplete | 262 | $14K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 54% | 4,518 | 4,141 | $556K |
| 92134 | 15% | 9,028 | 8,708 | $159K | |
| J0178 | Injection, aflibercept, 1 mg | 11% | 423 | 411 | $114K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.2% | 2,904 | 2,781 | $74K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.6% | 1,177 | 1,118 | $57K |
| J9035 | Injection, bevacizumab, 10 mg | 3.7% | 1,852 | 1,707 | $38K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.5% | 675 | 652 | $26K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 861 | 846 | $4K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 351 | 335 | $3K |
| 99072 | 0% | 208 | 191 | $0.00 | |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 0% | 12 | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEQLIN, EDWARD (PRESIDENT)